APTA - Ticker AI Digest

Aptamer Group PLC 📰 1
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (APTA) 1
APTA 06:01
Aptamer Group PLC
Optimer® Technology in Launched Library Prep Kit
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Aptamer Group plc (AIMAPTA) announced that Twist Bioscience Corporation has launched its **TrueAmp Library Preparation Kit**, incorporating Aptamers proprietary **Optimer® binder technology**. This kit represents a significant advancement in next-generation sequencing (NGS) library amplification workflows, offering enhanced stability at room temperature, high accuracy, and improved coverage of hard-to-sequence genomic regions. The partnership, initiated in December 2025 through a non-exclusive licensing agreement, combines Twist Biosciences expertise in synthetic biology and genomics with Aptamers Optimer® technology to address the growing NGS market. Dr. Arron Tolley, CEO of Aptamer Group, highlighted the real-world value of Optimer® in enabling market-ready products and expressed optimism for the collaborations continued success. The launch underscores the transformative potential of this technology in genomics research and clinical applications.
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 1
APTA 06:01
Aptamer Group PLC
Optimer® Technology in Launched Library Prep Kit
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Aptamer Group plc (AIMAPTA) announced that Twist Bioscience Corporation has launched its **TrueAmp Library Preparation Kit**, incorporating Aptamers proprietary **Optimer® binder technology**. This kit represents a significant advancement in next-generation sequencing (NGS) library amplification workflows, offering enhanced stability at room temperature, high accuracy, and improved coverage of hard-to-sequence genomic regions. The partnership, initiated in December 2025 through a non-exclusive licensing agreement, combines Twist Biosciences expertise in synthetic biology and genomics with Aptamers Optimer® technology to address the growing NGS market. Dr. Arron Tolley, CEO of Aptamer Group, highlighted the real-world value of Optimer® in enabling market-ready products and expressed optimism for the collaborations continued success. The launch underscores the transformative potential of this technology in genomics research and clinical applications.
Litigation 0
No items for this category on selected date.
NewContract 1
APTA 06:01
Aptamer Group PLC
Contract wins and first cash licensing receipts
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Aptamer Group PLC, a developer of next-generation synthetic binders for the life sciences industry, announced significant commercial progress on January 29, 2026. The company secured **£190,000 in new fee-for-service contracts and extensions**, including repeat business with top-tier pharmaceutical partners, bringing its FY26 fee-for-service order book to over **£2.1 million**. Additionally, Aptamer received its **first cash licensing receipts of £80,000** from a hot-start PCR Optimer® license, marking the transition to high-margin, recurring revenues.
Key highlights include
**Repeat contracts** with a top-10 global pharmaceutical company and other leading industry players, demonstrating sustained adoption of the Optimer® platform.
A new Optimer® development program for novel fertility solutions, with Aptamer retaining full intellectual property rights for potential downstream licensing.
The first cash licensing receipts are expected to contribute **15% of annual overhead** over the next three years, showcasing operational leverage.
A strong financial position with funding runway through **June 2027**, supporting continued revenue growth and progress toward cash-flow break-even.
CEO Dr. Arron Tolley emphasized the company’s progress in building a higher-quality, recurring revenue business, with confidence in delivering year-on-year growth and enhancing shareholder value.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 2
APTA 06:01
Aptamer Group PLC
Optimer® Technology in Launched Library Prep Kit
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Aptamer Group plc (AIMAPTA) announced that Twist Bioscience Corporation has launched its **TrueAmp Library Preparation Kit**, incorporating Aptamers proprietary **Optimer® binder technology**. This kit represents a significant advancement in next-generation sequencing (NGS) library amplification workflows, offering enhanced stability at room temperature, high accuracy, and improved coverage of hard-to-sequence genomic regions. The partnership, initiated in December 2025 through a non-exclusive licensing agreement, combines Twist Biosciences expertise in synthetic biology and genomics with Aptamers Optimer® technology to address the growing NGS market. Dr. Arron Tolley, CEO of Aptamer Group, highlighted the real-world value of Optimer® in enabling market-ready products and expressed optimism for the collaborations continued success. The launch underscores the transformative potential of this technology in genomics research and clinical applications.
APTA 06:01
Aptamer Group PLC
Contract wins and first cash licensing receipts
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Aptamer Group PLC, a developer of next-generation synthetic binders for the life sciences industry, announced significant commercial progress on January 29, 2026. The company secured **£190,000 in new fee-for-service contracts and extensions**, including repeat business with top-tier pharmaceutical partners, bringing its FY26 fee-for-service order book to over **£2.1 million**. Additionally, Aptamer received its **first cash licensing receipts of £80,000** from a hot-start PCR Optimer® license, marking the transition to high-margin, recurring revenues.
Key highlights include
**Repeat contracts** with a top-10 global pharmaceutical company and other leading industry players, demonstrating sustained adoption of the Optimer® platform.
A new Optimer® development program for novel fertility solutions, with Aptamer retaining full intellectual property rights for potential downstream licensing.
The first cash licensing receipts are expected to contribute **15% of annual overhead** over the next three years, showcasing operational leverage.
A strong financial position with funding runway through **June 2027**, supporting continued revenue growth and progress toward cash-flow break-even.
CEO Dr. Arron Tolley emphasized the company’s progress in building a higher-quality, recurring revenue business, with confidence in delivering year-on-year growth and enhancing shareholder value.

AI Crunch

Single-Ticker AI Crunch
APTA signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for Aptamer Group PLC. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full APTA AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for APTA on 2026-02-11.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
20126800
Enterprise Value
43277928
Public Float
66.72
Broker Target
180
Shares Out
3157145044
Long Interest
100
Short Interest
-
Exchange
LSE
Currency Code
GBX
ISIN
GB00BNRRP542
Market
None
Sector
Health Care
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2026-03-09
Net Debt
-568000.0
Cash
1059000.0
EPS
-
Net Income
-2424000.0
Revenue
1203000.0
Enterprise Value
43277928
Trailing PE
-
Forward PE
-
Price Sales TTM
14.6058
Price Book MRQ
8.4078
EV Revenue
12.8794
EV EBITDA
-5.0596

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
26.5526
Institutions As Of
2025-08-07
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
2
Sale Director Dealing
0
Purchase TR1
4
Sale TR1
2
Broker Coverage Rows
0
Institution Holders Tracked
4
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

1 live catalyst just hit APTA.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2026-02-11 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
1 Today
Catalyst Pulse
Aptamer Group PLC has fresh news flow feeding the chart narrative.
AI Charts Studio
APTA Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2026-02-11 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast 1.08%
RSI Gauge
Price Change
AI Forecast